NIH Clinical Center Search the Studies: Study Number, Study Title

Protocol Details

Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination with BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) with CV301 TRICOM in Advanced Solid Tumors (STAT)

This study is NOT currently recruiting participants.

Summary | Eligibility | Citations | Contacts




Sponsoring Institute

National Cancer Institute (NCI)

Recruitment Detail

Type: Completed Study; data analyses ongoing
Gender: Male & Female
Min Age: 18 Years
Max Age: 120 Years

Referral Letter Required


Population Exclusion(s)

Pregnant Women;


Checkpoint Inhibitor;
Combination Therapy;
Metastatic Cancer

Recruitment Keyword(s)



Metastatic Cancer;
Solid Tumors

Investigational Drug(s)

Bintrafusp alfa (M7824)

Investigational Device(s)



Drug: SX-682
Drug: M7824
Biological/Vaccine: MVA-BN-CV301
Biological/Vaccine: recombinant fowlpox viral (FPV)-CV301

Supporting Site

National Cancer Institute


Combination immunotherapy techniques are being explored to improve responses and enhance benefits in people with cancer. Researchers want to see if this type of treatment can help people with advanced solid tumors.


To find a safe dose of SX-682 in combined treatment with Bintrafusp alfa and BN-CV301 vaccines and to see if this treatment will cause tumors to shrink.


Adults age 18 and older with metastatic cancer may be eligible for the first part of the trial. Adults age 18 and older with metastatic triple negative breast cancer or p16 negative head and neck squamous cell cancer, and who are not candidates for curative surgery may be eligible for the second part of the trial.


Participants will be screened under a separate protocol.

Participants may have tumor biopsies. They will have physical exams. Their symptoms and medicines will be reviewed. They will have blood tests. They will have electrocardiograms to evaluate their heart.

Participants will have imaging scans of the chest, abdomen, and pelvis. They may have a procedure where a small tube with a tiny video camera is put into the nose to look at the throat if they have head and neck cancers.

Participants will get bintrafusp alfa through an intravenous catheter. For this, a small tube is put into an arm vein. They will get BN-CV301 vaccines as injections in the arm or thigh. They will take SX-682 by mouth twice a day. They will take the study drugs up to 2 years. They will keep a medicine diary.

Participants will have study visits every 2 weeks. They will have 1 or 2 follow-up visits within 30 days after they stop treatment. Then they will be monitored by phone or email for 2 years.

--Back to Top--



-Participants must have histologically or cytologically confirmed:

--Metastatic or locally advanced, Solid tumor (Cohort 1)


--Metastatic or locally recurrent, non-resectable Triple Negative Breast Cancer (TNBC), defined as ER < 10%, PR < 10% per immunohistochemistry (IHC) and HER 2 negative. HER2 negative or unamplified breast cancer is defined as IHC 0 or 1+ or IHC 2+ with FISH average HER2 copy number < 4.0 signals per cell or HER2/CEP17 < 2.0 with average HER2 copy number < 4.0 signals per cell.[89] HER2 testing must have been performed in a laboratory accredited by the College of American Pathology (CAP) or another accrediting entity (Cohort 2).


--Metastatic or locally recurrent, non-resectable p16 negative Head and Neck Squamous Cell Cancer (HNSCC). Oropharyngeal tumors must be negative for p16 overexpression by IHC per ASCO/CAP guidelines and in a CAP accredited lab.[90] All other head and neck malignancies do not require p16 testing (Cohort 3).

-Participants must have histologically or cytologically confirmed metastatic or locally advanced disease. Historical reports from a CAP accredited lab are acceptable.

-Subjects in Arms 1 and 2 may have disease that is measurable or non-measurable but evaluable disease (e.g. present on bone scan, rising tumor markers, non-measurable by RECIST but visible on CT scan). Participants with third space fluid (for example pleural effusions) as only site of disease will not be eligible. Subjects in Arm 3 must have measurable disease according to RECIST 1.1

-Participants must

--have received at least one prior systemic therapy for metastatic or locally advanced disease, unless there is no standard treatment available,


--not tolerate standard first line treatment,


--decline standard treatment after appropriate counseling has been provided.

Note: Participants in Arm 3, Cohort 3 who have PD-L1 positive TNBC must have progressed on atezolizumab + nab-paclitaxel. Participants in Arm 3, Cohort 3 (p16 negative HNSCC) must have progressed on or been intolerant to a regimen involving a platinum drug or cetuximab monotherapy.

-Age greater than or equal to 18 years.

-ECOG performance status 0 or 1.

-Participants must have adequate organ and marrow function as defined below:

--Absolute neutrophil count (ANC) >1,500/mcL

--Platelets >100,000/mcL

--Hemoglobin > 9 g/dL without a blood transfusion in the 14 days prior to enrollment.

--Total bilirubin < 1.5X upper limit of normal (ULN) OR in subjects with Gilbert s Syndrome, a total bilirubin < 3.0 x ULN

--AST(SGOT)/ALT(SGPT) <2.5 X institutional upper limit of normal OR in subjects with known liver metastasis, AST/ALT < 3.0 X ULN

--An estimated creatinine clearance (CrCl) > 60 mL/min/1.73 m2 using the Cockroft-Gault calculation (

-The effects of immunotherapies on the developing human fetus are unknown. For this reason and because immunotherapy agents as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) at the time of study entry, for the duration of study treatment and up to 6 months after the last dose of the study drug (s). Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.

-Participants with well-controlled HIV infection are eligible for trial as long as:

--On an effective anti-retroviral therapy (ART) > 4 weeks and with evidence of viral suppression defined as HIV viral load < 400 copies/mL at enrollment

--CD4+ count > 200 cells/microL at enrollment

-No reported opportunistic infections within 6 months prior to enrollment except for the following which will be allowed:

--Esophageal candidiasis treated within last 6 months or currently improving with antifungal treatment

--Oral and/or genital HSV treated within last 6 months or currently improving with antiviral treatment

--Mycobacterium avium infection in last 6 months or that has been treated for at least 1month.

-Immunomodulating drugs must be discontinued at least 1 weeks prior to enrollment for recent short course use (less than or equal to 14 days) or discontinued at least 4 weeks prior to enrollment for long term use (> 14 days).

-Participants must have a received their last treatment > 4 weeks or 5 half-lives of the last treatment drug, whichever is shorter before starting on trial.

-Participants with known history of hepatitis B (HBV) infection are eligible for trial as long as the HBV viral load is undetectable.

-Patients with known history of hepatitis C (HCV) infection must have been treated and cured (viral load is undetectable). For participants with HCV infection who are currently on treatment, they are eligible if they have an undetectable or unquantifiable HCV RNA 12 weeks or longer after definitive treatment completion.

-Subjects must be able to understand and be willing to sign a written informed consent document.


-Participants who are receiving any other investigational agents.

-Participants with active brain metastases or central nervous system metastasis (less than 28 days out from definitive radiotherapy or surgery of brain metastasis) are excluded from this clinical trial. However, patients with treated brain metastasis are eligible if there is no

magnetic resonance imaging (MRI) evidence of progression for 6 weeks after treatment is complete and the MRI within 28 days prior to enrollment. Participants requiring immunosuppressive doses of systemic corticosteroids (> 10 mg/day prednisone equivalent) for palliation are excluded. Patients with evidence of intratumoral or peritumoral brain metastasis hemorrhage on screening imaging are also excluded unless the hemorrhage of brain metastases is grade < 1 and has been stable on two consecutive imaging scans.

-History of allergic reactions attributed to compounds of similar chemical or biologic composition to any of study drugs

-Steroid use or active autoimmune disease that might deteriorate when receiving an immunostimulatory agent with the exception of:

--Diabetes type I, eczema, vitiligo, alopecia, psoriasis, hypo- or hyperthyroid disease or other mild autoimmune disorder not requiring immunosuppressive treatment;

--Participants requiring hormone replacement with corticosteroid are eligible if the steroids are administered only for the purpose of adrenal insufficiency and at doses of <10 mg of prednisone or equivalent per day;

--Administration of steroids for other conditions through a route known to result in a minimal systemic exposure (topical, intranasal, intro-ocular, or inhalation) is acceptable;

--Participants on physiologic doses of systemic intravenous or oral corticosteroid therapy (greater tahn or equal to the equivalent of prednisone 10 mg/day.

--The use of corticosteroids as premedication for contrast-enhanced studies which is allowed prior to enrollment.

-Participants with a history of serious intercurrent chronic or acute illness, such as cardiac or pulmonary disease, hepatic disease, bleeding diathesis or recent (within 3 months) clinically significant bleeding events or other illness considered by the Investigator as high risk for investigational drug treatment.

-History of second malignancy within 3 years of enrollment except for the following: adequately treated localized skin cancer, ductal carcinoma in situ, cervical carcinoma in situ, superficial bladder cancer or other localized malignancy which has been adequately treated.

-Receipt of any organ transplantation requiring ongoing immunosuppression including allogenic stem-cell transplant.

-Participants with bone metastases who have initiated denosumab or a bisphosphonate therapy within 28 days prior to enrollment. Continuation of prior therapy is allowed.

-Participants who have a QTcf interval > 475 msec or > 480 msec with a BBB on screening electrocardiogram.

-Participants with a personal or family history of long-QT syndrome or are on a concomitant drug that is known to cause significant QTc prolongation within 2 weeks or 5 half-lives (whichever is shorter) of enrollment

-Participants with heart failure (New York Heart Association [NYHA] class III or IV) or cerebrovascular accident within one year or acute myocardial infarction within one year.

-Participants unwilling to accept blood products or blood transfusions as medically indicated. As there is a risk of severe bleeding with M7824, participants must be willing to receive blood transfusions if medically necessary for their own safety

-Any other condition, which would, in the opinion of the Principal Investigator indicated the subject is a poor candidate for the clinical trial or would jeopardize the subject or the integrity of the data obtained.

-Pregnant women are excluded from this study because study drugs potential for teratogenic or abortifacient effects are unknown. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with study drugs, breastfeeding should be discontinued if the mother is treated with study drugs.

--Back to Top--


Not Provided

--Back to Top--


Principal Investigator

Referral Contact

For more information:

James L. Gulley, M.D.
National Cancer Institute (NCI)
(301) 480-7164

Deneise Francis, R.N.
National Cancer Institute (NCI)
National Institutes of Health
Building 10
Room 13N222
10 Center Drive
Bethesda, Maryland 20892
(240) 858-3974

NCI Referral Office
National Institute of Health Clinical Center (CC), 9000 Rockville Pike, Bethesda, Maryland 20892, United States: NCI Clinical Trials Referral Office

Clinical Trials Number:


--Back to Top--